Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nyxoah (NYXH)
NASDAQ:NYXH
Nyxoah (NYXH) Stock Price & Analysis
71 Followers
NYXH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.00 - $20.00
Previous Close$10.1
Volume3.60K
Average Volume (3M)44.41K
Market Cap
$288.40M
Enterprise Value$281.86M
Total Cash (Recent Filing)€21.61M
Total Debt (Recent Filing)€12.34M
Price to Earnings (P/E)-6.2
Beta0.60
Next Earnings
Aug 06, 2024EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding28,660,000
10 Day Avg. Volume35,454
30 Day Avg. Volume44,407
Standard Deviation0.28
R-Squared0.09
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.32
Price to Sales (P/S)93.38
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$18.65Price Target Upside88.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Nyxoah News
PremiumCompany Announcements
Nyxoah Excels in Q1 2024, Eyes FDA Approval
PremiumPre-Earnings
Nyxoah Sa (NYXH) Q1 Earnings Cheat Sheet
PremiumCompany Announcements
Nyxoah SA Welcomes New Chief Medical OfficerBulls Say, Bears Say
Bulls Say
Market ExpansionNyxoah's Genio system, a leadless, bilateral neurostimulation therapy for OSA, is poised to enter the large and underpenetrated US market, potentially reaching an estimated 510,000 patients.
Product EfficacyThe Genio system has demonstrated significant median AHI reduction and a high AHI responder rate, showing superior performance over competitors and addressing all sleeping positions, which may broaden its market appeal.
Strategic PartnershipsNyxoah's partnership with ResMed aims to increase awareness and therapy penetration for OSA, enhancing Genio's market presence and patient reach in the German market, with expected positive contributions in the near future.
Bears Say
Financial Health ConcernsWith a monthly cash burn of approximately €4.6M and a cash runway extending only into late 2024, there are looming concerns over the company's financial sustainability without securing further funding or increasing revenue.
Market PenetrationThe European market poses strong growth resistance, making it difficult for companies to expand and deepen their market presence.
Regulatory And Commercialization ChallengesGaining FDA approval and securing favorable reimbursement policies, along with the need for additional financing and building a US sales force, present significant challenges to commercialization efforts.
---
Ownership Overview
0.00%
Insiders
0.64% Mutual Funds
2.79% Other Institutional Investors
96.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
NYXH FAQ
What was Nyxoah’s price range in the past 12 months?
Nyxoah lowest stock price was $4.00 and its highest was $20.00 in the past 12 months.
What is Nyxoah’s market cap?
Currently, no data Available
When is Nyxoah’s upcoming earnings report date?
Nyxoah’s upcoming earnings report date is Aug 06, 2024 which is in 78 days.
How were Nyxoah’s earnings last quarter?
Nyxoah released its earnings results on May 14, 2024. The company reported -$0.451 earnings per share for the quarter, beating the consensus estimate of -$0.458 by $0.007.
Is Nyxoah overvalued?
According to Wall Street analysts Nyxoah’s price is currently Undervalued.
Does Nyxoah pay dividends?
Nyxoah does not currently pay dividends.
What is Nyxoah’s EPS estimate?
Nyxoah’s EPS estimate is -$0.47.
How many shares outstanding does Nyxoah have?
Nyxoah has 28,661,985 shares outstanding.
What happened to Nyxoah’s price movement after its last earnings report?
Nyxoah reported an EPS of -$0.451 in its last earnings report, beating expectations of -$0.458. Following the earnings report the stock price went up 7.203%.
Which hedge fund is a major shareholder of Nyxoah?
Among the largest hedge funds holding Nyxoah’s share is Iron Triangle Partners LP. It holds Nyxoah’s shares valued at 3M.
---
Nyxoah Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.65 (88.00% Upside)
$18.65 (88.00% Upside)
Blogger Sentiment
Bullish
NYXH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 78.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.9%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.33%
12-Months-Change
Fundamentals
Return on Equity
-40.68%
Trailing 12-Months
Asset Growth
-25.58%
Trailing 12-Months
Company Description
Nyxoah
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
---
NYXH Earnings Call
Q1 2024
0:00 / 0:00
---
NYXH Stock 12 Month Forecast
Average Price Target
$18.65
▲(88.00% Upside)
Technical Analysis
Best Analysts Covering NYXH
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+43.51%
reiterated a buy rating 6 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +43.51% per trade.
---